Skip to main content

22-02-2022 | ASCO GU 2022 | Conference coverage | Video

Add-on PARP inhibition in metastatic CRPC: PROpel and MAGNITUDE


David VanderWeele comments on the PROpel and MAGNITUDE trials investigating the addition of a PARP inhibitor to abiraterone in men with metastatic castration-resistant prostate cancer, focusing on the differences between the studies and the unanswered questions (5:20).